Novo Nordisk (NYSE:NVO) is betting on a risky drug development strategy, like re-engineering insulin to act selectively on the liver or only when blood sugar is high, according to the Wall Street Journal.
Nordisk has focused on developing fast-acting insulin to inject at mealtime and another variety for a steady supply of insulin throughout the day. Its most recent insulin product, Tresiba, provides a near-stable level of insulin in the blood for 40 hours. Tresiba sells for $443.85 for 15 milliliters, 10% higher than its predecessor Levemir.
Nordisk has focused on developing fast-acting insulin to inject at mealtime and another variety for a steady supply of insulin throughout the day. Its most recent insulin product, Tresiba, provides a near-stable level of insulin in the blood for 40 hours. Tresiba sells for $443.85 for 15 milliliters, 10% higher than its predecessor Levemir.
